Newshot

Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials

Summary

Isomorphic Labs, the AI drug-discovery platform that was spun out of Google’s DeepMind in 2021, has raised $5 Billion in a Series C funding round.

Original text(via TechCrunch AI)
Demis Hassabis, chief executive officer of DeepMind Technologies
Demis Hassabis, chief executive officer of DeepMind Technologies
Ram Iyer
Ram Iyer

Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials

Isomorphic Labs, the AI drug-discovery platform that was spun out of Google’s DeepMind in 2021, has raised $5 billion in a Series C funding round as it seeks to take its drug candidates to clinical trials.

The funding was co-led by Greenoaks and Sequoia Capital, with new investor Andreessen Horowitz and other investors also participating. All of the company’s existing backers, including Alphabet’s venture divisions GV and Capital G, Thrive Capital, MGX, Temasek, and the UK Sovereign AI Fund, also invested.

Isomorphic Labs builds an AI drug-design engine that uses a slew of simulation AI models that explore various areas of chemistry to help the company design drugs. The company, whose work builds on DeepMind’s breakthrough AlphaFold protein-folding AI model, said its program has yielded “positive preclinical results” in oncology and immunology. The lab has struck deals with pharma giants like Eli Lilly, Novartis, and Johnson & Johnson.

The new funding, which comes on the heels of a $2.1 billion Series B round in May, will be used to continue developing its drug-design engine, as well as to foray into more types of medicine.

The Series C is Isomorphic’s first fundraise since its founder and CEO, Demis Hassabis, left his position as head of DeepMind to focus on drug discovery, which also saw him moving into a chairman role at DeepMind. Hassabis and then-director of DeepMind John Jumper won the Nobel Prize in chemistry for the lab’s work on AlphaFold, a system that predicts the 3D structure of proteins with nothing more than their genetic sequence.

Isomorphic did not disclose its new valuation. Bloomberg reported earlier this month that the lab was looking to raise funding at a $50 billion valuation.

Get an Early Peek at the Next TechCrunch DisruptDisrupt, Startup Battlefield, and more will return next year, and you can be at the front of the line.Sign up for our waitlist

Newsletters

Subscribe for the industry’s biggest tech news

Related

  • Robotics Genesis AI raises $500 million to deploy glove-wearing robots Tim Fernholz 51 minutes ago
Genesis AI CEO and co-founder Zhou Xian with Eno, the company's flagship robot.
Genesis AI CEO and co-founder Zhou Xian with Eno, the company's flagship robot.

Genesis AI raises $500 million to deploy glove-wearing robots

  • Tim Fernholz
  • Biotech & Health Upside Foods can now make a million pounds of chicken a year without killing any animals Amanda Silberling 51 minutes ago

Upside Foods can now make a million pounds of chicken a year without killing any animals

  • Amanda Silberling
  • Media & Entertainment Hank Green is self-funding ClockwiseTV, a curated educational video platform for kids Amanda Silberling 51 minutes ago

Hank Green is self-funding ClockwiseTV, a curated educational video platform for kids

  • Amanda Silberling

Latest in Biotech & Health

  • In Brief Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials Ram Iyer 9 seconds ago

Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials

  • In Brief Science Corporation’s brain tech is worth $3.5 billion after new funding Tim Fernholz 24 minutes ago

Science Corporation’s brain tech is worth $3.5 billion after new funding

  • Tim Fernholz
  • Biotech & Health Upside Foods can now make a million pounds of chicken a year without killing any animals Amanda Silberling 51 minutes ago

Upside Foods can now make a million pounds of chicken a year without killing any animals

  • Amanda Silberling

The text above was extracted automatically from the source page and may miss images, tables or code blocks. The original is authoritative.

Published by TechCrunch AI
This site only summarises and aggregates; copyright stays with the original author. Headlines and summaries follow the source — where they differ, the original wins.
Read the original ↗